Cardiac Arrest Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Global Cardiac Arrest Treatment Market Trends and Insights

Growing Burden of Sudden Cardiac Arrest & Ageing Populations

Population ageing increases sudden cardiac death incidence, especially among adults over 65. The American Heart Association notes that 356,000 Americans experience out-of-hospital cardiac arrest each year, with survival remaining at 8-10%. Its 2030 Impact Goals target more than 50% bystander CPR and 20% AED use before EMS arrival to offset the 10% survival decline that occurs for every untreated minute. These goals push health systems to procure integrated device ecosystems rather than one-off equipment. Growing recognition of COVID-19-related myocardial micro-scarring in younger age groups further broadens the addressable patient pool. Consequently, the cardiac arrest treatment market continues to prioritize scalable platforms that combine monitoring, predictive software, and therapy delivery in a single continuum of care.

Public-Access Defibrillator Programmes and Legislation

State-mandated AED deployment in schools, sports arenas, and transit hubs expands device density and improves lay-rescuer readiness. South Carolina’s Smart Heart Act and Ohio’s House Bill 47 require both AED placement and cardiac emergency response plans, lowering legal barriers that once deterred facility managers. The Centers for Disease Control and Prevention offers a 13-point implementation toolkit that standardises procurement and maintenance, while federal proposals to reauthorise the Cardiac Arrest Survival Act strengthen liability protections. Connected AED platforms that feed status data into 911 dispatch networks therefore enjoy higher adoption, especially when bundled with subscription-based training modules.

Advances in Implantable & Wearable Defibrillator Technology

Device miniaturisation reduces implant risk and opens therapy to moderately at-risk cohorts. Medtronic’s 4.7 French OmniaSecure lead achieved a 97.5% defibrillation success rate during pivotal trials^{[1]Source: Medtronic plc, “OmniaSecure Clinical Trial Results,” medtronic.com} . Boston Scientific’s modular mCRM system links a subcutaneous ICD with a leadless pacemaker, posting a 98.8% inter-device communication success metric. Meanwhile, AI-enabled wearable defibrillators such as Element Science’s Jewel Patch extend protection past hospital discharge, bolstering the cardiac arrest treatment market by lowering rehospitalisation costs. Predictive algorithms embedded in cloud dashboards also alert clinicians before malignant arrhythmias manifest, shifting resource allocation from crisis response to prevention.

Miniaturised ECMO for Refractory Cardiac Arrest

Extracorporeal cardiopulmonary resuscitation (ECPR) yields 29.4% survival for refractory cases versus 2.4% with conventional CPR, per a multicentre propensity study. Medtronic’s portable VitalFlow ECMO system brings circuit priming and monitoring to the ambulance bay, letting teams initiate support within minutes of collapse. Registry data from the Extracorporeal Life Support Organization now list more than 100,000 survivors, validating field use when paired with rigorous training. Advances in biocompatible coatings and heparin-sparing circuits further counter previous bleeding risks, encouraging policy makers to reimburse ECPR in specialised EMS units.

Product Recalls & Device-Related Adverse Events

Quality lapses remain a central concern. Boston Scientific issued a Class I recall for certain Accolade pacemakers after 832 injuries and 2 deaths were linked to devices entering Safety Mode^{[2]Source: U.S. Food and Drug Administration, “Accolade Pacemaker Recall Notice,” fda.gov} . Abbott simultaneously recalled HeartMate pump accessories due to power unit failures, triggering the FDA’s pilot programme that accelerates public safety alerts for cardiovascular implants. These incidents reduce clinician confidence, delay new-product clearances, and push companies to allocate larger budgets to post-market surveillance, thereby slowing the overall cardiac arrest treatment market.

High Capital Cost & Reimbursement Gaps in Emerging Markets

Advanced defibrillators and ECMO circuits command premium price tags, yet reimbursement pathways in many emerging economies cover only basic resuscitation supplies. India’s device market still depends on 70% imports, creating affordability barriers for public hospitals. Variable evidence requirements across regulators also lengthen approval timelines, adding financing pressure on smaller exporters. Although private insurers in urban centres partly offset these gaps, rural populations often rely on out-of-pocket spending, limiting broader penetration of next-generation therapies.

Segment Analysis

By Product: Devices Drive Innovation While Drugs Face Pipeline Constraints

Devices contributed USD 3.66 billion in 2024, equal to 69.45% of total revenue. Technological leaps like AI-driven arrhythmia prediction and miniaturised ECMO propel this category toward a 6.67% CAGR, keeping the cardiac arrest treatment market size for devices ahead of pharmacologic alternatives. Defibrillators dominate hospital code carts, while drone-mounted AEDs extend reach to remote communities. Portable ECMO platforms win guideline endorsements for refractory cases, and mechanical circulatory support systems such as Impella add incremental hemodynamic stability. FDA approval of the VARIPULSE pulsed-field ablation system confirms regulators' willingness to fast-track high-impact devices, reinforcing vendor confidence in sustained R&D.

The drug segment accounts for the remaining revenue and grows at a slower pace as formulary constraints and generic competition bite. Class III agents like amiodarone remain standard for ventricular arrhythmias, yet shortages of vasopressors such as epinephrine sporadically disrupt critical-care supply chains. Investigational mRNA therapies, including AZD8601, mark the first significant mechanistic shift since dronedarone's 2009 launch, but large-scale efficacy data are pending. RNAi approaches that silence arrhythmogenic pathways show promise in preclinical settings, although commercial timelines extend beyond the current forecast window.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospital Dominance Challenged by Home Care Emergence

Hospitals and specialist cardiac centres captured 81.23% of 2024 revenue, underpinned by 24/7 catheterisation labs, ECMO suites, and intensive telemetry. Adoption of extracorporeal CPR protocols further solidifies this lead, with survival rates for in-centre ECPR reaching 29.4% compared with 2.4% for conventional approaches. Consolidation among health-system networks streamlines bulk purchases of connected defibrillators, elevating enterprise-wide uptime and maintenance compliance across multiple campuses.

The home and alternate care segment records a 6.01% CAGR and is forecast to gain incremental cardiac arrest treatment market size through 2030, driven by AI-enabled wearables that safeguard high-risk patients during the vulnerable post-discharge period. ZOLL Medical’s ResQCPR system reports a 49% one-year survival improvement when used with impedance threshold devices, encouraging payers to reimburse home-based solutions. Telemedicine legislation passed during the pandemic now supports remote programming of implantable devices, enlarging the data pipeline that clinicians use to anticipate deterioration. This decentralised model lowers rehospitalisation costs and aligns with value-based-care incentives, thereby accelerating adoption in both mature and emerging healthcare systems.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America holds 42.23% of 2024 revenue, benefiting from established EMS protocols, widespread AED saturation, and an FDA ecosystem that offers breakthrough device designations for life-saving tools. Federal liability shields under the Cardiac Arrest Survival Act nurture community responders, and the American Heart Association's targets push states to intensify public-access programmes. Integrated delivery networks negotiate fleet-wide service contracts for defibrillators and monitoring platforms, which sustains predictable replacement cycles. Large-scale field trials of drone-delivered AEDs in rural regions show response times reduced by 4-6 minutes, materially improving neurological outcomes.

Asia-Pacific is the fastest-growing territory at 7.93% CAGR, chiefly due to rising cardiovascular mortality and expanded emergency-care funding in urban provinces. Domestic manufacturers from China and Japan increase exports of cost-effective AEDs, challenging Western incumbents on price while meeting International Electrotechnical Commission (IEC) standards. Nevertheless, fragmented reimbursement landscapes still slow uptake of high-ticket ECMO and conduction-system pacing devices, keeping the cardiac arrest treatment market share for expensive capital equipment modest. Multilateral regulatory harmonisation projects, including the Asian Harmonisation Working Party, aim to trim approval times by synchronising dossier requirements—a factor that gradually reduces entry hurdles for global brands.

Europe delivers steady but cautious growth under unified medical-device regulations that emphasise clinical-evidence depth. The region champions clinical quality registries that feed outcome data into guideline updates, guiding hospitals toward evidence-backed purchases. Pilot drone networks in the Netherlands achieved sub-5-minute AED delivery to cardiac arrest scenes, prompting the European Union to fund cross-border replication studies nhs.uk. Budget pressures keep purchasing decisions under health-technology assessment review, yet outcome-based procurement models reward platforms that present clear reductions in out-of-hospital mortality. EU MDR transition costs remain a factor, but established suppliers with robust post-market surveillance capabilities maintain favourable status on tender lists